House E&C chair racks up cam­paign con­tri­bu­tions from more than 30 bio­phar­ma com­pa­nies so far in 2023

Rep. Cathy Mc­Mor­ris Rodgers (R-WA) chairs the most im­por­tant House com­mit­tee, En­er­gy and Com­merce, when it comes to bio­phar­ma in­ter­ests. And her 2024 re­elec­tion cam­paign has al­ready reaped more than $100,000 in con­tri­bu­tions in 2023 from more than 30 bio­phar­ma com­pa­nies, ac­cord­ing to fil­ings with the Fed­er­al Elec­tion Com­mis­sion.

Ef­fec­tive­ly serv­ing as the last line of de­fense for Re­pub­li­cans (with De­moc­rats con­trol­ling the Sen­ate and pres­i­den­cy) on all things phar­ma-re­lat­ed, Mc­Mor­ris Rodgers is ready­ing new leg­is­la­tion this fall around PBM re­forms, pan­dem­ic pre­pared­ness, and key drug short­ages that have caused de­layed or no ac­cess to com­mon can­cer treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER